A Comparison Between Recombinant Activated Factor VII (Aryoseven) and Novoseven in Patients With Congenital Factor VII Deficiency. (November 2015)

• Record Type: Journal Article
• Authors: Faranoush, M.; Abolghasemi, Hassan; Toogeh, Gh.; Karimi, M.; Eshghi, P.; Managhchi, M.; Hoorfar, H.; Dehdezi, B. Keikhaei; Mehrvar, A.; Khoeiny, B.; Kamyar, K.; Heshmat, R.; Baghaeipour, M. R.; Mirbehbahani, N. B.; Fayazfar, R.; Ahmadinejad, M.; Naderi, M.
• Is Part Of: Clinical and applied thrombosis/hemostasis. Volume 21:Number 8(2015)
• Page Start: 724
• Page End: 728
• Publication Date: 2015-11
• Subjects: hereditary -- factor VII -- deficiency -- AryoSeven -- NovoSeven -- Iran; Hemostasis -- Periodicals; Thrombosis -- Periodicals; 616.13
• DOI: 10.1177/1076029614522545
• Languages: English
• ISSNs: 1076-0296

Abstract

In order to establish the efficacy and biosimilar nature of AryoSeven to NovoSeven in the treatment of congenital factor VII (FVII) deficiency, patients received either agent at 30 μg/kg, intravenously per week for 4 weeks, in a randomized fashion. The primary aim was to compare FVII:coagulation activity (FVII:C), 20 minutes after recombinant activated FVII (rFVIIa) injection, in the 2 groups. A secondary measure was self-reported bleeding. The median interquartile baseline range of the plasma level of activated FVII (FVIIa) activity in the 2 groups was 1.6 (1.1-14.0) IU/dL and 5.0 (1.1-25.5) IU/dL. All patients achieved levels of FVIIa (FVII:C) >30 IU/dL, 20 minutes after the injection of rFVIIa. Bleeding was similar between the 2 groups, with a comparable decrease in severity and frequency compared to the last month prior to treatment. AryoSeven is similar to NovoSeven in increasing postinjection FVIIa activity as well as in clinical safety and efficacy.